History is a pretty good guide...in FY19 and 20 they expensed roughly 10% of R&D - see below and one of my earlier posts on this which shows the amount capitalised ($2.6m and $2m in FY20 and FY19 respectively). It doesn’t help that the board in its infinite wisdom has set management incentives based on EBITDA targets...chairman squarely to blame here.
Ann: Beam Quarterly Report - Further Growth in Cash Position, page-53
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
14.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.09M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 31014 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 35000 | 1 |
View Market Depth
| Last trade - 16.11pm 24/06/2025 (20 minute delay) ? |
| BCC (ASX) Chart |
Day chart unavailable